HK$ 36.06
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong margins and returns
About
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E
Target Price
The average target price of 2269.HK is 39 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
